Pulmonary Arterial Hypertension (PAH)

PRX-08066 is an orally active 5-HT2BR Antagonist with Vasodilation Effect for PAH

Pulmonary arterial hypertension (PAH) is an increased pulmonary arterial pressure caused by vasoconstriction and pulmonary vascular remodeling. In addition, 5-hydroxytryptamine (5-HT) plays a role in the development of PAH. Specifically,…

Cardiovascular Pulmonary Arterial Hypertension (PAH)

Seralutinib is an Inhaled Pdgfr Kinase Inhibitor

Edward Jenner 2021-03-30

Platelet-derived growth factor receptors (PDGF-R) are a kind of tyrosine kinase receptor on the cell surface of the PDGF family. Specifically, PDGF subunit-A and-B are important factors in regulating cell…